Neoadjuvant Chemo-Endocrine Therapy for Hormone Receptor Positive Breast Cancer: A Meta-Analysis
نویسندگان
چکیده
Background: Neoadjuvant chemotherapy has become the standard treatment for patients with locally advanced breast cancer. However, hormone receptor positive (especially human epidermal growth 2 negative) cancer show low response rate to neoadjuvant chemotherapy. Whether chemo-endocrine therapy (NCET) can improve pathological complete (pCR) of these remains controversial. Methods: A systematic literature search was conducted in PubMed, Embase, and Cochrane databases. Pooled odds ratio (OR) 95% confidence intervals (CI) calculated. Results: Five randomized controlled trials were included (N = 566). NCET did not significantly pCR (OR 1.35, CI 0.77–2.38, p 0.30). Conclusions: rates
منابع مشابه
Value of pre-treatment biomarkers in prediction of response to neoadjuvant endocrine therapy for hormone receptor-positive postmenopausal breast cancer.
OBJECTIVE To determine the predictive ability of biomarkers for responses to neoadjuvant endocrine therapy (NET) in postmenopausal breast cancer. METHODS Consecutive 160 postmenopausal women with T1-3N0-1M0 hormone receptor (HR)-positive invasive breast cancer were treated with anastrozole for 16 weeks before surgery. New slides of tumor specimens taken before and after treatment were conduct...
متن کاملNeoadjuvant Therapy for HER2-positive Breast Cancer.
In HER2-positive early breast cancer, neoadjuvant treatment with a combination of sequential chemotherapy and HER2-targeted therapy is currently the standard of care. This is followed by breast surgery, radiotherapy (if indicated), completion of 12 months of HER2-directed therapy, and - depending on the tumor biology - endocrine adjuvant therapy, and ultimately follow up. 10-year survival rates...
متن کاملEndocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.
PURPOSE To develop recommendations about endocrine therapy for women with hormone receptor (HR) -positive metastatic breast cancer (MBC). METHODS The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of evidence from 2008 through 2015 to create recommendations informed by that evidence. Outcomes of interest included sequencing of hormonal agents, ho...
متن کاملAdjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis
BACKGROUND In patients with hormone receptor-positive postmenopausal of early stage breast cancer, adjuvant endocrine monotherapies include letrozole, anastrozole, exemestane, toremifene and tamoxifen. But the optimum regimen remains controversial. METHODS PubMed, Cochrane Database and ClinicalTrials.gov were systematically reviewed of abstract for randomized-controlled trials (RCTs) to asses...
متن کاملStrategies to overcome endocrine therapy resistance in hormone receptor-positive advanced breast cancer
Use of endocrine therapies has made hormone receptor-positive breast cancer a manageable disease if diagnosed at an early stage. However, endocrine therapy resistance is a persistent problem in patients with advanced breast cancer. Ongoing research has identified a number of mechanisms that may mediate resistance, including estrogenindependent activation of the estrogen receptor; increased sign...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical and Experimental Obstetrics & Gynecology
سال: 2023
ISSN: ['0390-6663', '2709-0094']
DOI: https://doi.org/10.31083/j.ceog5004074